% alzhub.org library filter
% Source: https://alzhub.org/research?author=Wang+H&score_min=67
% 10 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{salloway2025-40390253,
  author  = {Salloway, S. and Pain, A. and Lee, E. and Papka, M. and Ferguson, M. B. and Wang, H. and Hu, H. and Lu, M. and others},
  title   = {{TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70293},
  pmid    = {40390253},
  url     = {https://doi.org/10.1002/alz.70293}
}

@article{zimmer2025-40063015,
  author  = {Zimmer, J. A. and Ardayfio, P. and Wang, H. and Khanna, R. and Evans, C. D. and Lu, M. and Sparks, J. and Andersen, S. and Lauzon, S. and Nery, E. S. M. and others},
  title   = {{Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials}},
  journal = {JAMA Neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.0065},
  pmid    = {40063015},
  url     = {https://doi.org/10.1001/jamaneurol.2025.0065}
}

@article{bai2021-34384464,
  author  = {Bai, B. and Vanderwall, D. and Li, Y. and Wang, X. and Poudel, S. and Wang, H. and Dey, K. K. and Chen, P. C. and others},
  title   = {{Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery}},
  journal = {Molecular neurodegeneration},
  year    = {2021},
  doi     = {10.1186/s13024-021-00474-z},
  pmid    = {34384464},
  url     = {https://doi.org/10.1186/s13024-021-00474-z}
}

@article{zhang2019-31427316,
  author  = {Zhang, H. and Huntley, J. and Bhome, R. and Holmes, B. and Cahill, J. and Gould, R. L. and Wang, H. and Yu, X. and others},
  title   = {{Effect of computerised cognitive training on cognitive outcomes in mild cognitive impairment: a systematic review and meta-analysis}},
  journal = {BMJ open},
  year    = {2019},
  doi     = {10.1136/bmjopen-2018-027062},
  pmid    = {31427316},
  url     = {https://doi.org/10.1136/bmjopen-2018-027062}
}

@article{wang2025-40172303,
  author  = {Wang, H. and Serap Monkul Nery, E. and Ardayfio, P. and Khanna, R. and Otero Svaldi, D. and Gueorguieva, I. and Shcherbinin, S. and Andersen, S. W. and Hauck, P. M. and Engle, S. E. and others},
  title   = {{Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70062},
  pmid    = {40172303},
  url     = {https://doi.org/10.1002/alz.70062}
}

@article{cheng2012-22372522,
  author  = {Cheng, G. and Huang, C. and Deng, H. and Wang, H.},
  title   = {{Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies}},
  journal = {Internal medicine journal},
  year    = {2012},
  doi     = {10.1111/j.1445-5994.2012.02758.x},
  pmid    = {22372522},
  url     = {https://doi.org/10.1111/j.1445-5994.2012.02758.x}
}

@article{sims2023-9857475c,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and Wang, H. and Monkul Nery, E. S. and Collins, E. C. and Solomon, P. and Salloway, S. and Apostolova, L. G. and Hansson, O. and Ritchie, C. and Brooks, D. A. and Mintun, M. and Skovronsky, D. M. and {TRAILBLAZER-ALZ 2 Investigators}},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  pmid    = {37459141}
}

@article{giugliano2017-28207168,
  author  = {Giugliano, R. P. and Mach, F. and Zavitz, K. and Kurtz, C. and Schneider, J. and Wang, H. and Keech, A. and Pedersen, T. R. and others},
  title   = {{Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial}},
  journal = {Clinical cardiology},
  year    = {2017},
  doi     = {10.1002/clc.22678},
  pmid    = {28207168},
  url     = {https://doi.org/10.1002/clc.22678}
}

@article{wang2025-40308765,
  author  = {Wang, H. and Pan, J. and Zhang, M. and Tan, Z.},
  title   = {{Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease}},
  journal = {Frontiers in pharmacology},
  year    = {2025},
  doi     = {10.3389/fphar.2025.1599048},
  pmid    = {40308765},
  url     = {https://doi.org/10.3389/fphar.2025.1599048}
}

@article{liu2024-39147783,
  author  = {Liu, L. and Wang, H. and Xing, Y. and Zhang, Z. and Zhang, Q. and Dong, M. and Ma, Z. and Cai, L. and others},
  title   = {{Dose-response relationship between computerized cognitive training and cognitive improvement}},
  journal = {NPJ digital medicine},
  year    = {2024},
  doi     = {10.1038/s41746-024-01210-9},
  pmid    = {39147783},
  url     = {https://doi.org/10.1038/s41746-024-01210-9}
}